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BACKGROUND

METHODS
Amplification

Chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients is
defined by sensory-motor neuropathy due to chemotherapeutic drug exposure.
Prediction of CIPN could be achieved by characterizing patient
pharmacogenetic (PGx)-related single-nucleotide polymorphism (SNP)
profiles. One common PGx gene- the cytochrome P450 (CYP) 2D6
(CYP2D6) is involved in the metabolism of ~21% of currently approved
medications, including chemotherapeutic drugs commonly prescribed for
cancer treatment. We used Single-Nucleotide Extension (SNE) and a Sanger
sequencing-based approach to genotype common clinical variations in CIPN
patients to profile PGx loci of CYP2D6 gene.
In a previous study, SNPs in the CYP2D6 gene were analyzed in 23 patients
with and without CIPN using Single-Nucleotide Extension (SNE) technology
in order to identify markers whose polymorphic profile might be used to
predict which patients are at high risk for developing CIPN. Long-range PCR
was used to amplify a 4kb section of the CYP2D6 gene. SNE, a multi-locus,
multiplexed genotyping method where a single fluorescently-labeled
nucleotide incorporated at the primer’s 3’ end identifies the presence/absence
of a specific polymorphism, was then performed on the 4 kb amplicons.
Results of the preliminary study are shown in Table 1 below. Twelve primer
pairs were split into two multiplexed panels for analysis.

The process of validation through Sanger sequencing first required optimization

for each of the primer pairs. Each primer pair was tested under multiple conditions
in order to determine the optimal conditions for patient samples. Patient samples
were then selected based off of the presence of a polymorphism according to the
previous study. These Patient DNA samples were diluted, then amplified
according to their conditions using the thermocycler for each of the primers. An
agarose gel was ran to determine which patient DNA was of adequate integrity to
generate amplicons for sequencing. Samples used for Sanger sequencing were
based on the results of these gels.
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Patient DNA amplifications resulting in single amplicon bands, as seen in Figure 1,
indicated successful and specific amplification. Patient sample amplicons were
cleaned up using ExoSAP. Following this enzymatic treatment, cycle sequencing
was performed using one of their respective amplification primers using BigDye
v3.1 cycle sequencing kit using manufacturer’s suggested protocols. Removal of
unincorporated fluorescent nucleotides was performed using a Dye-ex spin
column. Purified sequencing products were dried down using a SpeedVac and
resuspended in 10 ul of HiDi formamide, then loaded on a plate and analyzed on
the ABI 3500 capillary electrophoresis system using POP7 polymer and a 50 cm
capillary. Sequencing analysis software on the ABI 3500 was used to base call as
well as report the quality of the data.

70A

M

M

M

M

M

71A

M

M

N/A

N/A

N/A

80A

M

M

N/A

N/A

N/A

CYP2D6*6 - rs5030655
CYP2D6*10- rs1065852
CYP2D6*17- rs28371706

Analysis of Sanger Sequencing Data

Table 1. Results of preliminary study done with SNE.

HYPOTHESIS

Preliminary validation results indicated a low concordance between Sanger
sequencing results and the SNE assay findings in the original CIPN study. All
Patient DNA samples were used to generate amplicons containing the *6, *10 loci from the original CIPN study/SNE method were monomorphic by Sanger
and *17 polymorphisms (See example amplification results in Figure 1). sequencing (see Table 2).
Those patients generating the appropriately-sized amplicons (*6= 505 bp;
*6 rs1058164
*17 rs28371706
*17 rs28371702
*17 rs28371701
Amplicon *6R rs5030655
*10= 499 bp; *17= 505 bp) were subjected to Sanger sequencing. Positive
control genomic DNA confirmed the expected amplicon sizes. NTC, no
Patient ID
template controls indicated no contamination

RESULTS

Analyzing sanger sequencing data may be done in a variety of ways. The preferred
method of analyzing this data is using a tertiary software with an AB1 file to
analyze the chromatograms. The other method and the one used in comparing the
CYP2D6 data to the human genome involved the use of a text file of that data.
This procedure is done by using the best guess of the chromatogram in a text file.
The text file (.txt) is compared to the Human Reference Genome through BLAST.
This software provides data on pseudogenes, bands, transcript variants, and
identifies polymorphisms by showing gaps. The limitations to this method include
the possibility of low quality and the inability to identify heterozygotes. Though
even with these limitations, this software was used to identify a polymorphism
found in a patient's sample amplified with the *6 primer amplicon. Within most
patients as well as the Human Reference Genome, at position 297, a CC is found.
The polymorphism found in the particular patient’s sample indicated this with a
gap at this position. This patient’s "C" was changed to a "G". The BLAST
technique is useful in determining information as such.

Figure 1. Prior to sanger sequencing, amplification of the polymorphic regions of
CYP2D6 were performed for *6 (left), *10 (top right), and *17 (bottom right).

Amplicons for *6 were sequenced using the reverse primer while amplicons
for both *10 and *17 were sequenced using the forward primer. Sanger
sequencing data for *6 and *17 showed acceptable quality values (QV) and
peak threshold. *10 sequencing data failed the QV threshold and showed high
signal to noise ratio. Example sequencing electropherograms are shown in
Figure 2. Sequencing identified additional SNPs in *6 and *17 amplicons.
The *6 region showed synonymous rs1058164 polymorphisms while the *17
region had two intronic SNPs, namely rs28371702 and rs28371701. To
examine whether the synonymous rs1058164 *6 region SNP segregated with
CIPN, *6 amplicons from all 23 patients are currently being sequenced.

Table 2. Results of the Patient samples is highlighted within this table based on Sanger
Sequencing results. M- Monomorphic // Polymorphic

CONCLUSION
In the current study, we used a Sanger sequencing-based approach to validate
the previously generated SNE results for CYP2D6 polymorphisms in CIPN
patients. Polymorphic patient samples for *6, *10 and *17 SNPs were selected
for locus-specific amplification. Results from this analysis revealed that the
original SNE assay resulted in a high degree of false positive base calls. This
approach is known to show design and optimization-related variations and
limitations but calibration issues on the GeXP capillary electrophoresis system
(Beckman Coulter) used most likely also contributed to these anomalies.
Although, Sanger sequencing of amplicons containing the interrogated
CYP2D6 polymorphisms was a better system for evaluating SNPs for risk
assessment studies, this approach is also limited due to low sensitivity,
scalability, limit of detection, and thus discovery power. Future efforts to assess
CIPN risk using SNP profiles are currently utilizing a PGx panel
(ThermoFisher) run on an Ion Torrent platform, to more broadly detect low and
moderate frequency variants at higher coverage and perform association
analyses of these variants with CIPN.
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